Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

IRVING, Texas--(BUSINESS WIRE)--A global leader in the healthcare industry, McKesson Corporation (NYSE: MCK) will expand its existing partnership with the Centers for Disease Control (CDC) to support the U.S. government’s Operation Warp Speed (OWS) team as a centralized distributor of future COVID-19 vaccines and ancillary supplies needed to administer vaccinations.

McKesson to Distribute Future COVID-19 Vaccines in Support of Operation Warp Speed

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation today announced the appointment of Rebecca McKillican as Chief Executive Officer (CEO), McKesson Canada effective immediately. McKillican succeeds Domenic Pilla, who announced his plans to retire from the company in late 2019.

McKesson Canada Names Rebecca McKillican Chief Executive Officer

The big healthcare company faced COVID-19 headwinds. But its business improved more strongly than expected.

How McKesson's Mixed Q1 Results Still Beat Wall Street Estimates

McKesson Corporation (MCK) CEO Brian Tyler on Q1 2021 Results - Earnings Call Transcript

Shares of McKesson Corp. MCK, -2.24% climbed 1.9% in premarket trading Monday, after the drug distributor and health care services company reported fiscal first-quarter profit and revenue that beat expectations, and raised its full-year outlook.

McKesson's stock jumps after profit and revenue beats, raised outlook

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE:MCK) today reported results for the first quarter ended June 30, 2020. Fiscal 2021 First-Quarter Result Summary     First-Quarter ($ in millions, except per share amounts)   FY21   FY20   Change Revenues   $ 55,679     $ 55,728     — % Income from Continuing Operations1   445     429     4   Adjusted Earnings1,2   453     625     (28)   Earnings per Diluted Share1   2.72     2.27     20   Adjusted Earnings per Diluted Share1,2   2.77  

McKesson Reports Fiscal 2021 First-Quarter Results

McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

McKesson (MCK) to Post Q1 Earnings: What's in the Offing?

IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) today declared a regular dividend of 42 cents per share of common stock. The dividend will be payable on October 1, 2020, to stockholders of record on September 1, 2020.

McKesson Declares Quarterly Dividend July 29, 2020

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: McKesson (MCK) Q1 Earnings Expected to Decline

Count yourself lucky if you were a McKesson Corporation investor this year. While most of the stocks have fallen steeply, McKesson has grown more than 10%, increasing from $139 to $153 (as of July 20, 2020).

Should You Hold On To McKesson Corporation Stock?

AmerisourceBergen

Flex

Jabil

NIKE

Moving as much supply chain manufacturing moved out of China as possible will increase manufacturing in the United States.

Goldman Sachs Says US Onshoring From China May Be Huge: 5 Stocks to Buy Now

IRVING, Texas--(BUSINESS WIRE)--McKesson today announced that The Disability Equality Index (DEI) has named the company as one of its 2020 Best Places to Work for Disability Inclusion with a top-ranking score of 100. This is the fifth year in a row that McKesson has been recognized by the DEI as a top place to work and the second year in a row earning a top score.

McKesson Named One of the Best Places to Work for Disability Inclusion

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE:MCK) today announces changes to its reportable business structure. The Company has revised its reportable segments commencing in the second quarter of fiscal 2021. These moves reflect the Company’s continued focus on delivering new and innovative solutions to respond to the evolving needs of the healthcare industry, customers and patients. “McKesson has had a long history of leadership in the healthcare industry by advancing our busines

McKesson Realigns Organizational Structure to Better Serve Customers and Patients While Optimizing Growth

CVS Health

Waters

7 Picks For June 2020: 3 Of Them Are Severely Undervalued

Align Technology

Becton, Dickinson and Co.

Cardinal Health

Cooper Companies

Henry Schein

Labcorp Holdings Inc

Patterson Companies

DENTSPLY SIRONA

Near-Term Outlook Bleak for Medical Dental Supplies Industry

McKesson (MCK) reported earnings 30 days ago. What's next for the stock?

McKesson (MCK) Up 5.2% Since Last Earnings Report: Can It Continue?

These three companies dominate the industry, and all provide growth with a nice dividend.

Got $1,000? Buy These 3 Medical Distributor Stocks

Moderna

Target

Lowe's

Target, Lowe's, McKesson and Moderna were our top stock trades for Thursday. That said, here's what the charts look like now.

4 Top Stock Trades for Thursday: LOW, TGT, MRNA, MCK

McKesson (MCK) earnings for the healthcare company's fiscal fourth quarter of 2020 have MCK stock up Wednesday after beating estimates.
The post McKesson Earnings: MCK Stock Up 1% On Q4 Beat appeared first on InvestorPlace.

McKesson Earnings: MCK Stock Up 1% On Q4 Beat

The healthcare giant delivered across-the-board sales growth despite COVID-19 headwinds.

How McKesson Beat Wall Street Estimates in Q4

McKesson Corporation (MCK) CEO Brian Tyler on Q4 2020 Results - Earnings Call Transcript

McKesson (MCK) delivered earnings and revenue surprises of 4.15% and 5.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Surpasses Q4 Earnings and Revenue Estimates

Shares of McKesson Corp. MCK, +1.36% dropped 1.8% in premarket trading Wednesday, after the retail pharmacy and health care services company reported fiscal fourth-quarter earnings that beat expectations, but provided a downbeat earnings outlook citing "anticipated headwinds" as a result of the COVID-19 pandemic.

McKesson stock falls after earnings beat, but guidance was below expectations

Shares of McKesson (NYSE:MCK) fell 6% in pre-market trading after the company reported Q4 results.

McKesson: Q4 Earnings Insights

McCormick & Co (NYSE: MKC) shares are trading higher on Friday. UBS upgraded the stock from Neutral to Buy and raised its price target from $151 to $160.

News for McKesson Stock (MCK)